samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Service life is up to three times longer for new EPDM dia-phragms

Gemu


GEMÜ has developed a new EPDM diaphragm for use at high temperatures and steam for the pharmaceutical and biotechnological industries.

The development and manufacture of the new EPDM diaphragms was carried out completely within the GEMÜ group from the compound development to the final design and production. The diaphragms feature a greatly improved thermal load capacity. Steam tests at GEMÜ and at customers in production have revealed potentially up to three times longer service life in comparison with other diaphragms of the same design. An additional sealing bead has been integrated on the top which further improves external sealing.

The new diaphragm is FDA-conforming in accordance with title 21 paragraph 177.2600. It was tested by an independent institute in accordance with USP Class VI, is free from animal ingredients and is ROHS conform. At the same time, the design places emphasis on meeting the demands made on the EHEDG-certified original GEMÜ sealing system. The compound is peroxide cured and all compounding is carried out according to the strict quality specifica-tions of GEMÜ. Certified production is made exclusively for GEMÜ within the GEMÜ group. This ensures a fully integrated process and quality control.

The diaphragm (given an order designation “17“) is available in all sizes MG 8 - 100 (DN 4 - 100). The size 8 diaphragm is pushed into the compressor as cur-rent designs, the diaphragm sizes 10 - 100 are screwed positively into the com-pressor with a threaded pin. The new diaphragm fits easily in to the existing modular valve system and can be used and retrofitted for all GEMÜ diaphragm valves.

GEMÜ EPDM diaphragms can even be used in place of PTFE diaphragms eas-ily and without any conversion. The diaphragms can be changed in both direc-tions depending on the specific process conditions and preference of the user. The owner of a system can therefore react flexibly to a product or process changeover without expensive, major conversion measures. The greatly in-creased service life of the new diaphragm also reduces the running costs and ideally suits modern TCO concepts (Total-Cost of Ownership).

49.79.40.1.23.0
www.gemu.de
GEMÜ Gebrüder Müller Apparatebau GmbH & Co. KG, Fritz-Müller-Straße, 74653 Ingelfingen-Criesbach
 
Print this page
Send to a friend
   
spacer

News and Press Releases

Dr James Thomson to lead new Stem Cell and Regenerative Medicine Center within the new Morgridge Center for Discovery on UW-Madison campus

By Tom Still MADISON – There’s no one alive today who was around to witness the birth of Wisconsin’s dairy and cranberry industries in the late 1800s, or its rise as a manufacturing power in roughly the same era. But a new page in Wisconsin’s history of commerce is being written in our time – the emergence of stem-cell medicine. Recent events have solidified Wisconsin’s edge as a global leader in stem-cell research and the breakthroughs in human health it will produce (continued):
More info >>

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement